|
This newsletter is also
available as an Adobe PDF document.
Download
here
Vitamin C has a long history of use in
the treatment of various viral diseases. There has been
much confusion about vitamin C recently that has come
about mainly due to negative articles reported in the
media. Some of this has been around the use of vitamin C
for the common cold, some around the cardiovascular
effects of vitamin C and some around the role of vitamin
C in cancer. In particular, there have been statements
made that vitamin C contributes to arterial thickening
and thus atherosclerosis, and that vitamin C causes
cancer. Certainly the impression that is received by the
general public at large is one of alarm, but in short
time the general public tends to forget these concerns
and will be swayed by whatever the latest finding is, or
return to their previous use of vitamin C.
Without fail, the research that has painted
vitamin C in a bad light has been in vitro, and further
to this the experimental designs have been highly
isolated biochemical environments that have placed
abnormal presentations of vitamin C in contact with
cells etc. These conditions do not occur at all in vivo,
and in fact the in vivo evidence on all of these issues
overwhelmingly supports the clinical improvements gained
from the use of vitamin C. Further to this, on reading
the actual articles cited in the negative media reports,
the authors of the articles make no mention of vitamin C
causing atherosclerosis or cancer, these claims have
been extrapolated by the media. Vitamin C as ascorbic
acid, if placed in high enough concentrations with DNA
or exposed lipids, probably will have deleterious
effects on these substances, but really the same can be
said for any substance, even water. What we need to
focus on, to be of any clinical value, is appropriate in
vivo research, especially clinical research, and most
importantly the experience of thousands of clinicians,
past and present, who have used and continue to use
vitamin C appropriately because it gets them results.
There is a long history of the clinical use of
vitamin C, going all the way back to the 1930s and 40s.
Some of the earliest attempts at using vitamin C as a
therapeutic agent were with polio victims, and as the
doctors administering the vitamin C tried larger and
larger doses, their results improved significantly. One
of the earlier doctors to use higher doses of vitamin C
was Dr. Frederick Klenner, following on the heels of
positive research by Jungeblut in 1939 in which he
showed that the administration of ascorbic acid to
monkeys infected with poliomyelitis produced a distinct
reduction in the severity of the disease and enhanced
their resistance to it. Sabin attempted to reproduce
these findings, but although he found a major lethal
effect of vitamin C to polio virus in the test tube he
was unable to achieve these results in vivo. In
retrospect it is apparent that in the early days not a
lot of attention was paid to the size and frequency of
the dose given, accordingly results were variable.
In 1949, the first of a remarkable series of
papers appeared. Klenner described his successful
treatment of poliomyelitis, as well as a variety of many
other viral infections, using ascorbic acid. He gave the
rationale for his treatment, his technique in detail,
and his dramatic case histories. Klenner realized that
the secret was in the massive doses he employed, and he
tried to impart this knowledge to an unbelieving
profession. In his 1952 paper, Klenner further discussed
his ascorbic acid treatment of polio and comments on
Jungeblut's earlier work, stating:
"His results
were indecisive because the amount of vitamin C given
was inadequate to cope with the degree of infection.
Sabin's results were not as suggestive as Jungeblut's
because he, Sabin, used a greater dose of virus and less
Vitamin C.'
Klenner's suggested optimal dosage
rate for virus infections, calculated on the basis of a
70-kilogram (154-pound) adult, was 4.5 to 17.5 grams of
ascorbic acid given every two to four hours around the
clock (27 - 210 grams per day). This amount goes far
beyond anything that had been previously tried. He
records one successful case history after another in
these papers, as well as in his 1953 report.
With the success of Klenner, and in the absence
of any clear explanation as to why these high dose
vitamin C therapies were getting results, various other
doctors and scientists got involved with administration
of vitamin C in various doses. Linus Pauling conducted
some of the better technical research into vitamin C,
and in the meantime there were many doctors (mainly in
the united States) who were finding success against a
whole range of viruses and infectious diseases in
general, as long as they maintained high doses of
vitamin C. If the dose is right, vitamin C has been
found clinically to be effective against a range of
viruses, including herpes, human papilloma virus,
hepatitis viruses and more recently HIV/AIDS. What is
important here is that we have now covered a period in
excess of fifty years where medical practitioners have
consistently and repeatedly administered vitamin C in
high doses, and have continued to do so because they
have achieved excellent clinical results. Doctors who
start using vitamin C appropriately invariably do not
stop using it, rather they tend to expand the use of
vitamin C over its appropriate indications. Furthermore,
after fifty years of administration by thousands of
doctors the negative effects of vitamin C reported in
the media have simply not occurred clinically. Doctors
who have used vitamin C successfully do not stop
considering it when confronted by negative research,
however patients may not ask for vitamin C therapy as
often when there is a media headline.
There is
an enormous amount of published research, past and
present, covering the use of vitamin C in viral
disorders. While much of this is in vitro research,
there still exists an enormous amount of clinical
research, which is unfailingly positive, and supportive
of the position that vitamin C is a desirable and
effective therapeutic agent. It is clearly impossible to
exhaustively examine this research here (there are
roughly 25,000 such articles on PubMed), but some of the
more recent research covers the use of vitamin C in the
treatment of herpes virus, hepatitis A, HIV/AIDS and HPV
in cervical dysplasia and cervical cancer.
The
AIDS community uses Vitamin C heavily and in high doses.
The balance of evidence in research suggests that
vitamin C interferes with reverse transcriptase
activity, increasing the delay to sero-conversion and
decreasing the spread of virus from infected cells.
Harakeh et al (1) state “In chronically infected cells
expressing HIV at peak levels, ascorbate reduced the
levels of extracellular reverse transcriptase (RT)
activity (by greater than 99%) and of p24 antigen (by
90%) in the culture...” and “These results indicate that
ascorbate mediates an anti-HIV effect by diminishing
viral protein production in infected cells and RT
stability in extracellular virions.” Rivas et al have
found “Exposure to high concentrations of vitamin C
preferentially decreased the proliferation and survival
of the HIV-infected cells and caused decreased viral
production.” (2). Tang et al state “The highest levels
of total intake (from food and supplements) of vitamins
C and B1 and niacin were associated with a significantly
decreased progression rate to AIDS” (3) and another
article by Harakeh et al has found “Long-term
experiments showed that continuous presence of ascorbate
was necessary for HIV suppression” (4).
Vitamin
C is recommended by researchers (and clinicians) for
herpes treatment. Terekhina et al have concluded
“Impaired inhibition of hydroxy radical and a drop of
antioxidant enzymes activities and of the level of
ascorbic acid in herpes-infected cornea and tears are
factors in the pathogenesis of ophthalmic herpes.” (5)
Hovi et al carried out a randomized double-bind,
placebo-controlled clinical trial on the topical
treatment of recurrent mucocutaneous herpes with a
strong water solution of Ascoxal, an ascorbic
acid-containing pharmaceutical formulation with
mucolytic and non-specific antimicrobial activities.
They found “…a brief treatment with this ascorbic
acid-containing preparation resulted in statistically
significant clinical and antiviral effects, which calls
for further and more extensive studies with a more
intensive treatment schedule.” (6) Terezhalmy et al used
ascorbate in the treatment of fifty episodes of
recurrent herpes labialis. Their conclusion was that
“Optimum remission of symptoms was observed in 4.2 +/-
1.7 days with the 600 mg. dosage of the water-soluble
bioflavonoid-ascorbic acid complex. No adverse reactions
were reported by any of the patients who participated in
this investigation.” (7)
Vitamin C (and other
antioxidants) is receiving favourable research findings
in the prevention of cervical cell changes and cancer.
Goodman et al conducted a case-control study to examine
the association of plasma micronutrient concentrations
with the risk of cervical dysplasia after careful
adjustment for HPV infection. Tier findings state
“…results support existing evidence that high plasma
levels of antioxidants may reduce the risk of cervical
squamous intraepithelial lesions independent of HPV
infection” (8). A study by Herrero et al of 748 cases
and 1,411 hospital and community controls in four Latin
American countries evaluated the association between
certain elements of diet and invasive cervical cancer.
Their research finds that “The results are consistent
with those of other investigations and provide support
for a protective effect of vitamin C, carotenoids, and
other substances found in the same fruits and vegetables
against the development of invasive cervical cancer”
(9).
Many of the older papers, dating back
through the 1950s, 60s and 70s give even more exciting
indications of the use of vitamin C in therapy against
viruses. Research tends to get bogged down in
particulars, and in attempts to find the “mechanism” of
action of vitamin C (the major assumption being that
vitamin C works in isolation). This research
necessitates a very reduced approach to analysis;
designs incorporate the main known chemistry involved
and are almost inevitably in vitro studies. In living
systems the interactions are enormously more complex,
and in all but extremely well designed experiments bear
little resemblance to the results derived from a lot of
the in vitro research. This doesn’t mean that the in
vitro research is all bad science, rather that in
balance we should look hard at our mass of clinical
experience to make fundamental decisions about the use
of vitamin C in therapy.
Sincerely,
Dr
Ian Dettman Ph.D. (Biochemistry), B.Sc. Hons (Biochem),
F.R.M.I.T. (Biochem, Microbiology), N.D.
F.A.C.B.S., F.A.N.T.A., R.A.C.I., M.A.S.M.
ACNEM, A.I.M.S., A.P.S., N.H.A.A., A.T.M.S
Research references:
1. Suppression of
human immunodeficiency virus replication by ascorbate in
chronically and acutely infected cells. Harakeh S
Jariwalla RJ Pauling L Proc Natl Acad Sci U S A 1990
Sep;87(18):7245-9. 2. Increased uptake and
accumulation of vitamin C in human immunodeficiency
virus 1-infected hematopoietic cell lines. Rivas CI Vera
JC Guaiquil VH Velasquez FV Borquez-Ojeda OA Carcamo JG
Concha II Golde DW J Biol Chem 1997 Feb
28;272(9):5814-20 3. Dietary micronutrient intake
and risk of progression to acquired immunodeficiency
syndrome (AIDS) in human immunodeficiency virus type 1
(HIV-1)-infected homosexual men. Tang AM Graham NM
Kirby AJ McCall LD Willett WC Saah AJ Am J Epidemiol
1993 Dec 1;138(11):937-51. 4. Comparative study of
the anti-HIV activities of ascorbate and
thiol-containing reducing agents in chronically
HIV-infected cells. Harakeh S Jariwalla RJ Am J
Clin Nutr 1991 Dec;54(6 Suppl):1231S-1235S. 5.
Lacrimal and salivary antioxidants in viral infection
Terekhina NA Petrovich IA Batueva RA Sosnin DI Vesna
VA Klin Lab Diagn 1998 Jan;(1):13-5. 6. Topical
treatment of recurrent mucocutaneous herpes with
ascorbic acid-containing solution. Hovi T Hirvimies
A Stenvik M Vuola E Pippuri R Antiviral Res 1995
Jun;27(3):263-70. 7. The use of water-soluble
bioflavonoid-ascorbic acid complex in the treatment of
recurrent herpes labialis. Terezhalmy GT Bottomley
WK Pelleu GB Oral Surg Oral Med Oral Pathol 1978
Jan;45(1):56-62. 8. The association of plasma
micronutrients with the risk of cervical dysplasia in
Hawaii. Goodman MT Kiviat N McDuffie K Hankin JH
Hernandez B Wilkens LR Franke A Kuypers J Kolonel LN
Nakamura J Ing G Branch B Bertram CC Kamemoto L Sharma S
Killeen J Cancer Epidemiol Biomarkers Prev 1998
Jun;7(6):537-44. 9. A case-control study of nutrient
status and invasive cervical cancer. I. Dietary
indicators. Herrero R Potischman N Brinton LA Reeves
WC Brenes MM Tenorio F de Britton RC Gaitan E Am J
Epidemiol 1991 Dec 1;134(11):1335-46.
|